Should I buy or sell Amneal Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares. View AMRX analyst ratings or view top-rated stocks .

What is Amneal Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 12 month target prices for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $6.25 to $8.00. On average, they predict the company's share price to reach $7.31 in the next twelve months. This suggests a possible upside of 36.7% from the stock's current price. View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts .

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the start of the year. Since then, AMRX stock has decreased by 11.9% and is now trading at $5.35. View the best growth stocks for 2024 here .

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 15.9% from the March 15th total of 2,070,000 shares. Based on an average daily trading volume, of 1,530,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 2.2% of the company's stock are short sold. View Amneal Pharmaceuticals' Short Interest .

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our AMRX earnings forecast .

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, May 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its quarterly earnings results on Friday, March, 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analysts' expectations of $630.67 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 126.04% and a negative net margin of 3.51%.

What ETFs hold Amneal Pharmaceuticals' stock?

ETFs with the largest weight of Amneal Pharmaceuticals (NASDAQ:AMRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) .

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Friday, March, 1st. The company provided EPS guidance of 0.530-0.630 for the period, compared to the consensus EPS estimate of 0.600. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.08%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel , Gautam Patel , Joseph Todisco , Nikita Shah and Tpg Gp A, Llc. View institutional ownership trends .

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free AMRX Stock Alerts

$5.39

+0.03 (+0.56%)

(As of 12:46 PM ET)

Compare

Today's Range: $5.33
▼
$5.43
50-Day Range: $5.31
▼
$6.34
52-Week Range: $1.58
▼
$6.46

Volume: 282,506 shs
Average Volume: 1.49 million shs
Market Capitalization: $1.65 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.31

Get Amneal Pharmaceuticals alerts:

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 36.7% Upside
$7.31 Price Target
Short Interest: Healthy
2.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 12.00%
From $0.50 to $0.56 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

326th out of 918 stocks

Pharmaceutical Preparations Industry

141st out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Amneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Amneal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.17% of the float of Amneal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Amneal Pharmaceuticals has recently increased by 15.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Amneal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amneal Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMRX.

3.8

News and Social Media Coverage

News Sentiment
Amneal Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Amneal Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
7 people have searched for AMRX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
7 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amneal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
26.56% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Amneal Pharmaceuticals are expected to grow by 12.00% in the coming year, from $0.50 to $0.56 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amneal Pharmaceuticals is -17.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amneal Pharmaceuticals is -17.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Amneal Pharmaceuticals has a P/B Ratio of 76.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMRX Stock News Headlines

April 16, 2024 | businesswire.com

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

April 15, 2024 | finance.yahoo.com

Amneal Pharmaceuticals (NASDAQ:AMRX) shareholders are still up 235% over 1 year despite pulling back 8.0% in the past week

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

April 11, 2024 | finance.yahoo.com

Alkermes' Innovations Are Transforming Mental Health Treatments

April 10, 2024 | businesswire.com

Amneal to Report First Quarter 2024 Results on May 3, 2024

April 9, 2024 | stocknews.com

3 Lucrative Pharma Stocks to Diversify Your Investments

April 8, 2024 | msn.com

Bausch Health drops after suing Amneal Pharma over Xifaxan generic

April 5, 2024 | marketwatch.com

Bausch Health Sues Amneal Over IBS Treatment Patent

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

March 28, 2024 | businesswire.com

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

March 27, 2024 | msn.com

Amneal gains FDA greenlight to develop Ciprodex generic for ear infections

March 25, 2024 | markets.businessinsider.com

Amneal Pharma Receives FDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension

March 25, 2024 | marketwatch.com

Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination

March 25, 2024 | finance.yahoo.com

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

March 18, 2024 | stocknews.com

Top 3 Pharma Innovators to Watch Closely

March 8, 2024 | msn.com

Amneal Pharmaceuticals (NASDAQ:AMRX) Presents a Compelling Option for Value Investors

March 4, 2024 | finance.yahoo.com

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2023 Earnings Call Transcript

March 4, 2024 | markets.businessinsider.com

Amneal Pharmaceuticals (AMRX) Gets a Buy from Barclays

March 3, 2024 | seekingalpha.com

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript

March 1, 2024 | markets.businessinsider.com

Strong Growth Ahead: Buy Rating for Amneal Pharmaceuticals Amidst Promising Product Launches and Financial Performance

March 1, 2024 | msn.com

Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?

March 1, 2024 | seekingalpha.com

Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

March 1, 2024 | marketwatch.com

Amneal Pharmaceuticals Stock Rises 13% After 4Q Results

March 1, 2024 | benzinga.com

Amneal Pharmaceuticals: Q4 Earnings Insights

March 1, 2024 | msn.com

Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $617M misses by $17.86M

March 1, 2024 | markets.businessinsider.com

Amneal Pharmaceuticals Up 20% In Pre-market - Update

March 1, 2024 | finance.yahoo.com

Amneal Pharmaceuticals Inc (AMRX) Reports Mixed 2023 Financial Results

See More Headlines

Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AMRX
Previous Symbol: NASDAQ:AMRX
CUSIP: N/A
CIK: 1723128
Web: amneal.com
Phone: 908-947-3120
Fax: 908-947-3146
Employees: 7,700
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.31
High Stock Price Target: $8.00
Low Stock Price Target: $6.25
Potential Upside/Downside: +35.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 10.78
P/E Growth: N/A
Net Income: $-83,990,000.00
Net Margins: -3.51%
Pretax Margin: -1.68%
Return on Equity: 126.04%
Return on Assets: 4.00%

Debt

Debt-to-Equity Ratio: 121.31
Current Ratio: 1.63
Quick Ratio: 0.94

Sales & Book Value

Annual Sales: $2.39 billion
Price / Sales: 0.69
Cash Flow: $1.33 per share
Price / Cash Flow: 4.04
Book Value: $0.07 per share
Price / Book: 77.00

Miscellaneous

Outstanding Shares: 307,010,000
Free Float: 225,466,000
Market Cap: $1.65 billion
Optionable: Optionable
Beta: 1.33

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Chirag K. Patel (Age 57)
Co-Founder, Co-CEO, President & Director
Comp: $1.71M
Mr. Chintu Patel R.Ph. (Age 52)
Co-Founder, Co-CEO & Director
Comp: $1.7M
Mr. Anastasios G. Konidaris (Age 57)
Executive VP & CFO
Comp: $1.04M
Mr. Jason B. Daly Esq. (Age 50)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $779.06k
Ms. Nikita Shah (Age 45)
Executive VP & Chief Human Resources Officer
Comp: $848.83k
Mr. Andrew S. Boyer (Age 58)
Executive VP & Chief Commercial Officer of Generics
Comp: $1.2M
Mr. Anthony DiMeo
Head of Investor Relations
Mr. Gregory Sgammato
Senior Vice President of Corporate Development
Mr. Pranav Mehta
Senior VP of Strategic Sourcing & Supply Management
Dr. Sanjay Kumar Jain Ph.D.
Chief Quality Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.
What is Amneal Pharmaceuticals' stock price target for 2024?: 4 brokerages have issued 12 month target prices for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $6.25 to $8.00. On average, they predict the company's share price to reach $7.31 in the next twelve months. This suggests a possible upside of 36.7% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.
How have AMRX shares performed in 2024?: Amneal Pharmaceuticals' stock was trading at $6.07 at the start of the year. Since then, AMRX stock has decreased by 11.9% and is now trading at $5.35.
View the best growth stocks for 2024 here.
Are investors shorting Amneal Pharmaceuticals?: Amneal Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,400,000 shares, an increase of 15.9% from the March 15th total of 2,070,000 shares. Based on an average daily trading volume, of 1,530,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 2.2% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest.
When is Amneal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our AMRX earnings forecast.
How can I listen to Amneal Pharmaceuticals' earnings call?: Amneal Pharmaceuticals will be holding an earnings conference call on Friday, May 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amneal Pharmaceuticals' earnings last quarter?: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its quarterly earnings results on Friday, March, 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.07. The firm had revenue of $616.98 million for the quarter, compared to analysts' expectations of $630.67 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 126.04% and a negative net margin of 3.51%.
What ETFs hold Amneal Pharmaceuticals' stock?: ETFs with the largest weight of Amneal Pharmaceuticals (NASDAQ:AMRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).Invesco Russell 2000 Dynamic Multifactor ETF (OMFS).
What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?: Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Friday, March, 1st. The company provided EPS guidance of 0.530-0.630 for the period, compared to the consensus EPS estimate of 0.600. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.6 billion.
Who are Amneal Pharmaceuticals' major shareholders?: Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.08%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends.
How do I buy shares of Amneal Pharmaceuticals?: Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

AMRX Stock Price History

AMRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMRX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™